NEW YORK, Aug. 18, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Moderna, Inc. (NASDAQ:MRNA) and Sprinklr, Inc. (NYSE:CXM). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Moderna, Inc. (NASDAQ:MRNA)

Class Period: January 18, 2023 – June 25, 2024

Lead Plaintiff Deadline: October 8, 2024

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, the Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (1) mRNA-1345 was less effective than Defendants had led investors to believe; (2) accordingly, mRNA-1345's clinical and/or commercial prospects were overstated; and (3) as a result, the Company's public statements were materially false and misleading at all relevant times.

For more information on the Moderna class action go to: https://bespc.com/cases/MRNA

Sprinklr, Inc. (NYSE: CXM)

Class Period: March 29, 2023 – June 5, 2024

Lead Plaintiff Deadline: October 14, 2024

According to the complaint, on December 6, 2023, Sprinklr announced strong 3Q 2024 results and then reduced its estimated growth for the 4Q and full year 2025. The Company blamed it on "subscription renewal pressures" caused by macro headwinds and the "over-rotation" of sales to its Contact Center as a Service ("CCaaS") market. On an earnings call in September 2023, CEO Ragy Thomas stated that the Company's investments in AI and the CCaaS opportunity were main contributors to its customer growth. Subsequently, in March several changes were made to the Company's C-level positions. Analysts commenting on the reduced estimates mention surprise at the timing and shift in the Company's sales strategy. Following this news, Sprinklr's stock price fell by $5.59 per share, or approximately 34% to close at $11.11 per share.

On June 5, 2024, Sprinklr again announced significantly reduced growth expectations, this time cutting fiscal year 2025 projections another three percent, down to a mere 7% annual growth, again attributing the losses to reduced customer retention in Sprinklr's core business and macro headwinds. The price of Sprinklr's common stock declined dramatically. From a closing market price of $10.84 per share on June 5, 2024 Sprinklr's stock price fell to $9.20 per share on June 6, 2024, a decline of more than 15% in the span of one day.

For more information on the Sprinklr class action go to: https://bespc.com/cases/CXM

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact Information:

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com